The Role of Chemical Messenger Signaling in Removing Alzheimer's Pathology From the Brain.
About the Research Project
Program
Award Type
Standard
Award Amount
$285,000
Active Dates
September 01, 2020 - August 31, 2024
Grant ID
A20201187S
Co-Principal Investigator(s)
Roxana Carare, MD, PhD, University of Southampton
Timothy Collier, PhD, Michigan State University
Goals
The contribution of cerebral amyloid (Abeta) angiopathy (CAA) and cerebrovascular pathology to the progression of Alzheimer’s disease (AD) has received renewed interest in the field. This proposal expounds upon compelling preliminary data to test that degeneration of the locus coeruleus (LC) and cholinergic basal forebrain (CBF) projection systems contributes to cognitive impairment through their damaging effects on intramural peri-arterial drainage (IPAD) of Abeta contributing to AD/CAA. If successful, this proposal will advance the clinical rationale for targeting LC/CBF-mediated IPAD as a disease modifying strategy.
Summary
The contribution of cerebral amyloid (Aβ) angiopathy (CAA) to the progression of Alzheimer’s disease (AD) has received renewed interest in the field. This proposal expounds upon compelling preliminary data to test that degeneration of the locus coeruleus (LC) and cholinergic basal forebrain (CBF) projection systems contributes to cognitive impairment through their damaging effects on the vascular clearance of Aβ, thus contributing to AD/CAA. If successful, this proposal will advance the clinical rationale for targeting LC/CBF-mediated cerebrovascular dysfunction as a disease modifying strategy.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD